PrEP Not Reaching Most Who Could Potentially Benefit
A new CDC study suggests that only a small percentage of Americans who could potentially benefit from pre-exposure prophylaxis (PrEP), a daily pill for HIV prevention, have been prescribed it. In the first detailed analysis by race and by risk group, CDC researchers found while two-thirds of those who could potentially benefit from PrEP are African American or Latino, these groups account for the smallest percentage of prescriptions to date.
Key Findings
• |
In 2015, there were approximately 1.1 million Americans who could potentially benefit from PrEP according to CDC guidelines, including:
|
|||||||||
• |
However, during a similar time period (September 2015 – August 2016), prescriptions filled at retail pharmacies or mail order services included as few as:
"One of our most powerful tools for HIV prevention remains largely on pharmacy shelves." – Jonathan Mermin, MD, MPH, Director of CDC's National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention
"Closing gaps is an important step for PrEP." – Eugene McCray, MD, Director of CDC's Division of HIV/AIDS Prevention
"We now have a powerful picture of where PrEP's potential impact could be greatest." – Dawn K. Smith, MD, MPH, MS, Epidemiologist and Medical Officer in CDC's Division of HIV/AIDS Prevention |